{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-328180","form_type":"8-K","ticker":"RGNX","cik":"0001590877","company_name":"REGENXBIO Inc.","filed_at":"2021-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.183825+00:00","generated_at":"2026-06-28T09:12:53.971981+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"REGENXBIO reports positive interim Phase II data for RGX-314; 71.8% reduction in anti-VEGF injections at 6 months","bullets":["RGX-314 well tolerated across 50 patients in Cohorts 1-3; no drug-related SAEs.","Cohort 2 (wet AMD) at 6 months: mean BCVA stable (-0.1 letters from Day1); 71.8% reduction in anti-VEGF burden; 40% injection-free.","Cohort 1 (diabetic retinopathy) at 3 months: stable BCVA +2.6 letters vs +0.4 control.","Company plans additional updates; enrollment ongoing in higher-dose cohorts 4/5."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-328180","json":"https://secwatch.observer/filing/0001193125-21-328180.json","markdown":"https://secwatch.observer/filing/0001193125-21-328180.md","text":"https://secwatch.observer/filing/0001193125-21-328180.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590877/000119312521328180/0001193125-21-328180-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590877/000119312521328180/d142076d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T09:12:53.971981+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}